introduction of prednisone and vincristine failed to increase response rates or to prolong survival. The IVth MRC Myelomatosis Trial was designed to assess the value of vincristine in first line treatment of myelomatosis. It admitted 530 previously untreated patients who were randomised to receive either: courses of melphalan and prednisone alone or courses of the same drugs plus vincristine. Patients reaching plateau phase were randomised either to stop first line treatment or to continue this for a further year.
Patients and methods
This report is based on entry into the MRC IVth Trial in Myelomatosis. A total of 530 patients were entered from 1st March 1980 to 28th February 1982 This analysis is based on follow-up to 1st February 1984, the median follow-up time being 23 months at which time 319 patients had died. Entry criteria for the trial were as follows:
All patients had at least two of the following three criteria: (Cooper et al., 1984) .
Results
Survival in relation to allocated Ist line treatment The overall survival in the trial analysed by allocated treatment is shown in Figure 1 . There is no significant difference between the groups (x2X= 0.02 P>0.5). The median duration of survival for all patients was 26 months. There were 78 patients admitted to the trial who died within the first 100 days from randomisation. Many of these deaths may have occurred too soon for treatment to have been effective. Analysis of survival of those patients surviving > 100 days from entry also revealed no significant difference in survival =20.50, P>0.5).
When stratified according to the prognostic groups identified previously (Medical Research Figure 2 . There was a small trend toward a better survival in the "stop" group but this was not significant (X2 = 1.47, P = 0.2). This result was not affected by the treatment allocated at initial presentation (X2= 1.53, P=0.2 after adjustment for initial therapy). The level of response to treatment achieved in patients who were rerandomised at plateau was assessed (Table III) (Cooper et al., 1984) .
Discussion
An analysis of a number of 4 and 5-drug regimens used by the South West Oncology Group Alexanian & Dreicer, 1984) suggested that patients on regimens including vincristine fared better than those treated with protocols not including this agent. This viewpoint was expressed in a BMJ editorial (1978) and the results reported by Lee et al. (1974 ) Salmon (1975 and later Case et al. (1977) were also cited as confirmatory evidence. The Cancer and Leukaemia group B on the other hand carried out a randomised controlled trial in which vincristine and prednisone were added late during first line therapy. They failed to show that the addition of these agents at 22 weeks had either increased the rate of subsequent objective responses or prolonged survival in patients treated with melphalan or nitrosoureas . (Cornwell et al, 1982) . Our trial was designed to assess the value of the addition of vincristine, at doses and intervals used by the South West Oncology group to standard treatment with intermittent melphalan and prednisone and no benefit could be found. Recently Barlogie et al. (1984) have reported effective treatment of advanced myeloma refractory to alkylating agents, with a regimen consisting of high dose dexamethasone, and prolonged infusion of vincristine and doxorubicin. It is difficult to assess what role vincristine may have had in achieving these responses.
There is no clear concensus in the literature about the optimal duration of first line treatment in myelomatosis. To some extent this will depend upon the treatment used. As response rates vary from patient to patient, it seems logical to relate length of first line treatment to plateau phase rather than to a fixed time from starting therapy. In the third MRC trial patients were treated initially for 1 year only and were then rerandomised to receive maintenance or no further chemotherapy (MRC Working Party on Leukaemia in Adults, 1980a). The duration of survival was slightly better in those patients not receiving maintenance but this difference is not significant. The South West Oncology Group (1975) assessed the value of continuing melphalan and prednisone for more than 1 year and concluded that this was of no major value.
Other reports have appeared supporting the policy of limiting the duration of first line treatment Paccagnella et al. 1983) . Arguments in favour of restricting the length of first line treatment include: (i) an improved chance of achieving second responses to chemotherapy when disease subsequently progresses; (ii) reduction in myelotoxicity, infection and secondary leukaemia and (iii) improved quality of life in patients on stable plateau phase who are not receiving chemotherapy. The present study has provided objective evidence from a large randomised trial that first line therapy with intermittent melphalan and prednisone should not be continued after plateau phase has been reached. It remains to be shown whether the introduction of different cytotoxic agents at this stage might be of benefit. However, cytokinetic studies of patients' disease at plateau phase indicate that residual disease may be inherently resistant to further chemotherapy (Hokanson et al., 1977; Durie et al., 1980) .
